Novo Nordisk (NVO) has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, a Reuters review of LinkedIn posts shows, Maggie Fick and Soren Jeppesen report. The cuts include staff in manufacturing roles, from quality control to production line technicians, at Novo’s major Clayton, North Carolina, plant and other facilities in the state, according to the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Stock Surges Amid Drug Discounts
- Costco (COST) Will Sell Discounted Ozempic and Wegovy for Those without Insurance
- Moderately bullish activity in Novo Nordisk with shares down 0.92%
- Novo Nordisk upgraded to Buy from Hold at HSBC (yesterday)
- Analysts Reaffirm Buy Ratings on Pfizer Stock (PFE) after Trump Pricing Deal